Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections

Li, 2005, Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria, Int J Antimicrob Agents, 25, 11, 10.1016/j.ijantimicag.2004.10.001 Jain, 2004, Multidrug-resistant acinetobacter infections: an emerging challenge to clinicians, Ann Pharmacother, 38, 1449, 10.1345/aph.1D592 Livermore, 2004, The need for new antibiotics, Clin Microbiol Infect, 10, 1, 10.1111/j.1465-0691.2004.1004.x Livermore, 2003, The threat from the pink corner, Ann Med, 35, 226, 10.1080/07853890310001609 Falagas, 2005, Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria, BMC Infect Dis, 5, 24, 10.1186/1471-2334-5-24 Falagas, 2005, Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections, Clin Infect Dis, 40, 1333, 10.1086/429323 Karabinis, 2004, Colistin for Klebsiella pneumoniae-associated sepsis, Clin Infect Dis, 38, e7, 10.1086/380461 Livermore, 2005, Tigecycline: what is it, and where should it be used?, J Antimicrob Chemother, 56, 611, 10.1093/jac/dki291 Dean, 2003, Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1, Antimicrob Agents Chemother, 47, 972, 10.1128/AAC.47.3.972-978.2003 Evans, 1999, Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria, Ann Pharmacother, 33, 960, 10.1345/aph.18426 Sueke, 2005, Using intrathecal colistin for multidrug resistant shunt infection, Br J Neurosurg, 19, 51, 10.1080/02688690500080729 Reina, 2005, Safety and efficacy of colistin in acinetobacter and pseudomonas infections: a prospective cohort study, Intensive Care Med, 31, 1058, 10.1007/s00134-005-2691-4 Quinn, 2005, Intrathecal colistin and sterilization of resistant Pseudomonas aeruginosa shunt infection, Ann Pharmacother, 39, 949, 10.1345/aph.1E485 Obritsch, 2005, Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options, Pharmacotherapy, 25, 1353, 10.1592/phco.2005.25.10.1353 Mubareka, 2005, Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis, Crit Care, 9, 29, 10.1186/cc3036 Michalopoulos, 2005, Cure of multidrug-resistant Acinetobacter baumannii bacteraemia with continuous intravenous infusion of colistin, Scand J Infect Dis, 37, 142, 10.1080/00365540410020776-1 Michalopoulos, 2005, Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic, Clin Microbiol Infect, 11, 115, 10.1111/j.1469-0691.2004.01043.x Katragkou, 2005, Successful treatment of multidrug-resistant Acinetobacter baumannii central nervous system infections with colistin, J Clin Microbiol, 43, 4916, 10.1128/JCM.43.9.4916-4917.2005 Kasiakou, 2005, Cure of post-traumatic recurrent multiresistant Gram-negative rod meningitis with intraventricular colistin, J Infect, 50, 348, 10.1016/j.jinf.2004.05.008 Gump, 2005, Intrathecal colistin for treatment of highly resistant pseudomonas ventriculitis. Case report and review of the literature, J Neurosurg, 102, 915, 10.3171/jns.2005.102.5.0915 Falagas, 2005, Toxicity after prolonged (more than four weeks) administration of intravenous colistin, BMC Infect Dis, 5, 1, 10.1186/1471-2334-5-1 Bukhary, 2005, Treatment of nosocomial meningitis due to a multidrug resistant Acinetobacter baumannii with intraventricular colistin, Saudi Med J, 26, 656 Berlana, 2005, Use of colistin in the treatment of multiple-drug-resistant gram-negative infections, Am J Health Syst Pharm, 62, 39, 10.1093/ajhp/62.1.39 Bratu, 2005, Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents, J Antimicrob Chemother, 56, 128, 10.1093/jac/dki175 Bratu, 2005, Multidrug-resistant Pseudomonas aeruginosa in Brooklyn, New York: molecular epidemiology and in vitro activity of polymyxin B, Eur J Clin Microbiol Infect Dis, 24, 196, 10.1007/s10096-005-1294-x Sarria, 2004, Use of intravenous polymyxin B during continuous venovenous hemodialysis, Eur J Clin Microbiol Infect Dis, 23, 340, 10.1007/s10096-004-1106-8 2006 2005 2004 Li, 2003, Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis, J Antimicrob Chemother, 52, 987, 10.1093/jac/dkg468 Li, 2003, Stability of colistin and colistin methanesulfonate in aqueous media and plasma studied by high-performance liquid chromatography, Antimicrob Agents Chemother, 47, 1364, 10.1128/AAC.47.4.1364-1370.2003 Li, 2004, Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate, J Antimicrob Chemother, 53, 837, 10.1093/jac/dkh167 Li, 2001, In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis, Antimicrob Agents Chemother, 45, 781, 10.1128/AAC.45.3.781-785.2001 Barnett, 1964, Sodium sulphomethyl derivatives of polymyxins, Br J Pharmacol, 23, 552 Li, 2003, Use of high-performance liquid chromatography to study the pharmacokinetics of colistin sulfate in rats following intravenous administration, Antimicrob Agents Chemother, 47, 1766, 10.1128/AAC.47.5.1766-1770.2003 Bergen, 2006, Colistin methanesulfonate is an inactive pro-drug of colistin against Pseudomonas aeruginosa, Antimicrob Agents Chemother, 50, 1953, 10.1128/AAC.00035-06 2005 Levin, 1999, Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, Clin Infect Dis, 28, 1008, 10.1086/514732 Michalopoulos, 2005, Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis, Crit Care, 9, R53, 10.1186/cc3020 Conway, 2000, Safety and tolerability of bolus intravenous colistin in acute respiratory exacerbations in adults with cystic fibrosis, Ann Pharmacother, 34, 1238, 10.1345/aph.19370 Conway, 1997, Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis, Thorax, 52, 987, 10.1136/thx.52.11.987 Markou, 2003, Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients, Crit Care, 7, R78, 10.1186/cc2358 Ledson, 1998, Four years' experience of intravenous colomycin in an adult cystic fibrosis unit, Eur Respir J, 12, 592, 10.1183/09031936.98.12030592 Reed, 2001, The pharmacokinetics of colistin in patients with cystic fibrosis, J Clin Pharmacol, 41, 645, 10.1177/00912700122010537 Gales, 2001, Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines, J Clin Microbiol, 39, 183, 10.1128/JCM.39.1.183-190.2001 2005 Li, 2002, Simple method for assaying colistin methanesulfonate in plasma and urine using high-performance liquid chromatography, Antimicrob Agents Chemother, 46, 3304, 10.1128/AAC.46.10.3304-3307.2002 Li, 2001, A simple method for the assay of colistin in human plasma, using pre-column derivatization with 9-fluorenylmethyl chloroformate in solid-phase extraction cartridges and reversed-phase high-performance liquid chromatography, J Chromatogr B Biomed Sci Appl, 761, 167, 10.1016/S0378-4347(01)00326-7 Li, 2005, Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration, Antimicrob Agents Chemother, 49, 4814, 10.1128/AAC.49.11.4814-4815.2005 Al-Khayyat, 1973, Pharmacologic and toxicologic studies with the polymyxins. II. Comparative pharmacologic studies of the sulfate and methanesulfonate salts of polymyxin B and colistin in dogs, Chemotherapy, 19, 82, 10.1159/000221443 Froman, 1970, Serum and urine levels following parenteral administration of sodium colistimethate to normal individuals, J Urol, 103, 210, 10.1016/S0022-5347(17)61924-4 Schulin, 2002, In vitro activity of the aerosolized agents colistin and tobramycin and five intravenous agents against Pseudomonas aeruginosa isolated from cystic fibrosis patients in southwestern Germany, J Antimicrob Chemother, 49, 403, 10.1093/jac/49.2.403 Trotman, 2005, Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy, Clin Infect Dis, 41, 1159, 10.1086/444500 Jimenez-Mejias, 2000, Successful treatment of multidrug-resistant Acinetobacter baumannii meningitis with intravenous colistin sulfomethate sodium, Eur J Clin Microbiol Infect Dis, 19, 970, 10.1007/s100960000400 Jimenez-Mejias, 2002, Cerebrospinal fluid penetration and pharmacokinetic/pharmacodynamic parameters of intravenously administered colistin in a case of multidrug-resistant Acinetobacter baumannii meningitis, Eur J Clin Microbiol Infect Dis, 21, 212, 10.1007/s10096-001-0680-2 Le Brun, 2002, Dry powder inhalation of antibiotics in cystic fibrosis therapy, part 2: inhalation of a novel colistin dry powder formulation: a feasibility study in healthy volunteers and patients, Eur J Pharm Biopharm, 54, 25, 10.1016/S0939-6411(02)00044-9 Ratjen, 2006, Pharmacokinetics of inhaled colistin in patients with cystic fibrosis, J Antimicrob Chemother, 57, 306, 10.1093/jac/dki461 Eickhoff, 1965, Polymyxin B and colistin: in vitro activity against Pseudomonas aeruginosa, Am J Med Sci, 249, 172 Catchpole, 1997, A reassessment of the in-vitro activity of colistin sulphomethate sodium, J Antimicrob Chemother, 39, 255, 10.1093/jac/39.2.255 Tam, 2005, Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa, Antimicrob Agents Chemother, 49, 3624, 10.1128/AAC.49.9.3624-3630.2005 Gunderson, 2003, Synergistic activity of colistin and ceftazidime against multiantibiotic-resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model, Antimicrob Agents Chemother, 47, 905, 10.1128/AAC.47.3.905-909.2003 Li J, Rayner CR, Nation RL, Owen R, Tan KE, Spelman D. In vitro pharmacodynamics of colistin and colistin methanesulfonate against Acinetobacter baumannii. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington, DC, USA; Dec 16–19, 2005. Montero, 2002, Efficacy of colistin versus beta-lactams, aminoglycosides, and rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant Acinetobacter baumannii, Antimicrob Agents Chemother, 46, 1946, 10.1128/AAC.46.6.1946-1952.2002 Young, 1992, Role of Pseudomonas aeruginosa outer membrane protein OprH in polymyxin and gentamicin resistance: isolation of an OprH-deficient mutant by gene replacement techniques, Antimicrob Agents Chemother, 36, 2566, 10.1128/AAC.36.11.2566 Nicas, 1980, Outer membrane protein H1 of Pseudomonas aeruginosa: involvement in adaptive and mutational resistance to ethylenediaminetetraacetate, polymyxin B, and gentamicin, J Bacteriol, 143, 872, 10.1128/JB.143.2.872-878.1980 Makela, 1978, Isolation and genetic characterization of polymyxin-resistant mutants of salmonella, FEMS Microbiol Lett, 3, 323, 10.1111/j.1574-6968.1978.tb01963.x Groisman, 1997, Regulation of polymyxin resistance and adaptation to low-Mg2+ environments, J Bacteriol, 179, 7040, 10.1128/jb.179.22.7040-7045.1997 Conrad, 1989, Fatty acid alterations and polymyxin B binding by lipopolysaccharides from Pseudomonas aeruginosa adapted to polymyxin B resistance, Antimicrob Agents Chemother, 33, 1724, 10.1128/AAC.33.10.1724 Vaara, 1981, Characterization of the lipopolysaccharide from the polymyxin-resistant pmrA mutants of Salmonella typhimurium, FEBS Lett, 129, 145, 10.1016/0014-5793(81)80777-6 Vaara, 1979, Decreased binding of polymyxin by polymyxin-resistant mutants of Salmonella typhimurium, J Bacteriol, 139, 664, 10.1128/JB.139.2.664-667.1979 Gunn, 1996, PhoP-PhoQ activates transcription of pmrAB, encoding a two-component regulatory system involved in Salmonella typhimurium antimicrobial peptide resistance, J Bacteriol, 178, 6857, 10.1128/jb.178.23.6857-6864.1996 Moskowitz, 2004, PmrAB, a two-component regulatory system of Pseudomonas aeruginosa that modulates resistance to cationic antimicrobial peptides and addition of aminoarabinose to lipid A, J Bacteriol, 186, 575, 10.1128/JB.186.2.575-579.2004 Campos, 2004, Capsule polysaccharide mediates bacterial resistance to antimicrobial peptides, Infect Immun, 72, 7107, 10.1128/IAI.72.12.7107-7114.2004 Gatzeva-Topalova, 2004, Crystal structure of Escherichia coli ArnA (PmrI) decarboxylase domain. A key enzyme for lipid A modification with 4-amino-4-deoxy-L-arabinose and polymyxin resistance, Biochemistry, 43, 13370, 10.1021/bi048551f Mathur, 2004, The Vibrio cholerae ToxR-regulated porin OmpU confers resistance to antimicrobial peptides, Infect Immun, 72, 3577, 10.1128/IAI.72.6.3577-3583.2004 Winfield, 2005, Transcriptional regulation of the 4-amino-4-deoxy-L-arabinose biosynthetic genes in Yersinia pestis, J Biol Chem, 280, 14765, 10.1074/jbc.M413900200 Hoiby, 2005, Eradication of early Pseudomonas aeruginosa infection, J Cyst Fibros, 4, 49, 10.1016/j.jcf.2005.05.018 Littlewood, 2000, A ten year review of Colomycin, Respir Med, 94, 632, 10.1053/rmed.2000.0834 Conway, 2003, Antibiotic treatment of multidrug-resistant organisms in cystic fibrosis, Am J Respir Med, 2, 321, 10.1007/BF03256660 Kitzis MD, Acar JF, Ly A, Goldstein FW. Very high frequency of mutation to colistin resistance in gram-negative bacteria. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington, DC, USA; Oct 30–Nov 2, 2004. Pai H, Byeon J. Mutant prevention concentration of polymyxin B for the clinical isolates of multi-drug resistant Pseudomonas aeruginosa. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington, DC, USA; Oct 30–Nov 2, 2004. Gilad J, Eskira S, Riesenberg K, Schlaeffer F, Hyam E, Borer A. Emergence of nosocomial colistin-resistant Acinetobacter baumannii. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington, DC, USA; Dec 16–19, 2005. Beringer, 2001, The clinical use of colistin in patients with cystic fibrosis, Curr Opin Pulm Med, 7, 434, 10.1097/00063198-200111000-00013 Garnacho-Montero, 2003, Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP, Clin Infect Dis, 36, 1111, 10.1086/374337 Al-Aloul, 2005, Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use, Pediatr Pulmonol, 39, 15, 10.1002/ppul.20138 Bouallegue-Godet, 2005, Nosocomial outbreak caused by Salmonella enterica serotype Livingstone producing CTX-M-27 extended-spectrum beta-lactamase in a neonatal unit in Sousse, Tunisia, J Clin Microbiol, 43, 1037, 10.1128/JCM.43.3.1037-1044.2005 Naas, 2006, Emergence of PER and VEB extended-spectrum {beta}-lactamases in Acinetobacter baumannii in Belgium, J Antimicrob Chemother, 58, 178, 10.1093/jac/dkl178 Bishara, 2005, Antibacterial susceptibility of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli, Isr Med Assoc J, 7, 298 Wolinsky, 1962, Neurotoxic and nephrotoxic effects of colistin in patients with renal disease, N Engl J Med, 266, 759, 10.1056/NEJM196204122661505 Ryan, 1969, Colistimethate toxicity. Report of a fatal case in a previously healthy child, JAMA, 207, 2099, 10.1001/jama.1969.03150240119022 Koch-Weser, 1970, Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy, Ann Intern Med, 72, 857, 10.7326/0003-4819-72-6-857 Bosso, 1991, Toxicity of colistin in cystic fibrosis patients, DICP Ann Pharmacother, 25, 1168 Perkins, 1964, Apnea with intramuscular colistin therapy, JAMA, 190, 421, 10.1001/jama.1964.03070180019004 Elwood, 1966, Acute renal failure associated with sodium colistimethate treatment, Arch Intern Med, 118, 326, 10.1001/archinte.1966.00290160026006 Adler, 1971, Nonoliguric renal failure secondary to sodium colistimethate: a report of four cases, Am J Med Sci, 262, 109, 10.1097/00000441-197108000-00006 Etherington, 2004, Urinary N-acetyl -β-D-glucosaminidase [NAG] in adults with CF—a marker of nephrotoxicity?, J Cyst Fibros, 3, S49 Kasiakou, 2005, Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis, Antimicrob Agents Chemother, 49, 3136, 10.1128/AAC.49.8.3136-3146.2005 Stein, 2002, Colistin: an antimicrobial for the 21st century?, Clin Infect Dis, 35, 901, 10.1086/342570 Daram, 2005, Colistin-associated acute renal failure: revisited, South Med J, 98, 257, 10.1097/01.SMJ.0000152540.45539.98 Li, 2005, Colistin-associated acute renal failure: revisited, South Med J, 98, 1229, 10.1097/01.smj.0000189912.79366.18 Berg, 1998, Modulation of polymyxin B effects on mammalian urinary bladder, Am J Physiol, 275, F204 Berg, 1996, Effects of polymyxin B on mammalian urinary bladder, J Membr Biol, 154, 119, 10.1007/s002329900137 Lewis, 2004, Colistin interactions with the mammalian urothelium, Am J Physiol Cell Physiol, 286, C913, 10.1152/ajpcell.00437.2003 Kasiakou, 2005, Cure of multidrug-resistant Acinetobacter baumannii fixation device-related orthopedic infections in two patients with intravenous colistin, Microb Drug Resist, 11, 287, 10.1089/mdr.2005.11.287 Fulnecky, 2005, Amikacin and colistin for treatment of Acinetobacter baumannii meningitis, J Infect, 51, e249, 10.1016/j.jinf.2005.04.003 Linden, 2003, Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa, Clin Infect Dis, 37, E154, 10.1086/379611 Fernandez-Viladrich, 1999, Successful treatment of ventriculitis due to carbapenem-resistant Acinetobacter baumannii with intraventricular colistin sulfomethate sodium, Clin Infect Dis, 28, 916, 10.1086/517243 Vasen, 2000, Intrathecal use of colistin, J Clin Microbiol, 38, 3523, 10.1128/JCM.38.9.3523-3523.2000 Mordasini, 1997, Inhalational antibiotic therapy in patients with cystic fibrosis and pseudomonas infection, Schweiz Med Wochenschr, 127, 905 Westerman, 2004, Effect of nebulized colistin sulphate and colistin sulphomethate on lung function in patients with cystic fibrosis: a pilot study, J Cyst Fibros, 3, 23, 10.1016/j.jcf.2003.12.005 Marchetti, 2004, Early antibiotic treatment of Pseudomonas aeruginosa colonisation in cystic fibrosis: a critical review of the literature, Eur J Clin Pharmacol, 60, 67, 10.1007/s00228-004-0735-2 Jensen, 1987, Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection, J Antimicrob Chemother, 19, 831, 10.1093/jac/19.6.831 Frederiksen, 1997, Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis, Pediatr Pulmonol, 23, 330, 10.1002/(SICI)1099-0496(199705)23:5<330::AID-PPUL4>3.0.CO;2-O Littlewood, 1985, Nebulized Colomycin for early pseudomonas colonization in cystic fibrosis, Lancet, 1, 865, 10.1016/S0140-6736(85)92222-6 Alothman, 2005, Bronchial constriction and inhaled colistin in cystic fibrosis, Chest, 127, 522, 10.1378/chest.127.2.522 Maddison, 1994, Nebulized colistin causes chest tightness in adults with cystic fibrosis, Respir Med, 88, 145, 10.1016/0954-6111(94)90028-0 Dodd, 1997, Effect of tonicity of nebulised colistin on chest tightness and pulmonary function in adults with cystic fibrosis, Thorax, 52, 656, 10.1136/thx.52.7.656 Conway, 2005, Nebulized antibiotic therapy: the evidence, Chron Respir Dis, 2, 35, 10.1191/1479972305cd045rs Hamer, 2000, Treatment of nosocomial pneumonia and tracheobronchitis caused by multidrug-resistant Pseudomonas aeruginosa with aerosolized colistin, Am J Respir Crit Care Med, 162, 328, 10.1164/ajrccm.162.1.9910071 Green, 1992, Nebulized colistin (polymyxin E) for AIDS-associated Pseudomonas aeruginosa pneumonia, Int J STD AIDS, 3, 130, 10.1177/095646249200300212 Kwa, 2005, Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa, Clin Infect Dis, 41, 754, 10.1086/432583 Giamarellos-Bourboulis, 2001, Interactions of colistin and rifampin on multidrug-resistant Acinetobacter baumannii, Diagn Microbiol Infect Dis, 40, 117, 10.1016/S0732-8893(01)00258-9 Giamarellos-Bourboulis, 2003, In vitro interaction of colistin and rifampin on multidrug-resistant Pseudomonas aeruginosa, J Chemother, 15, 235, 10.1179/joc.2003.15.3.235 Hogg, 1998, In-vitro activity of the combination of colistin and rifampicin against multidrug-resistant strains of Acinetobacter baumannii, J Antimicrob Chemother, 41, 494, 10.1093/jac/41.4.494 Rynn, 1999, In vitro assessment of colistin's antipseudomonal antimicrobial interactions with other antibiotics, Clin Microbiol Infect, 5, 32, 10.1111/j.1469-0691.1999.tb00095.x Petrosillo, 2005, Combined colistin and rifampicin therapy for carbapenem-resistant Acinetobacter baumannii infections: clinical outcome and adverse events, Clin Microbiol Infect, 11, 682, 10.1111/j.1469-0691.2005.01198.x